TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31611626
Drug: Intensive block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive block therapy
Study: 26108190
Drug: Intravenous lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous lacosamide 400 mg/day for 8 days
Study: 18374614
Drug: Roflumilast 500
Normalized name: ROFLUMILAST 500MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 500 microg once daily for 28 days
Study: 16869482
Drug: Alternative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative treatment (discussion of problems)
Study: 12590404
Drug: Fluvoxamine (100-250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100-250 mg/day)
Study: 11465584
Drug: Drug that
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug that may increase the probability of survival by 20%
Study: 30753091
Drug: Acetaminophen and
Normalized name: Acetaminophen and Aspirin Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen and verbal behavior modification
Study: 24226720
Drug: Other oral
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other oral nutritional supplements
Study: 18032219
Drug: 1,000 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 g/d of B12 for participants with MMA > 271 nmol/L
Study: 18032219
Drug: 0, 25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0, 25, or 100 microg/d of B12 for participants with MMA <= 271 nmol/L
Study: 11881102
Drug: telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: telmisartan 40 mg
Study: 17996511
Drug: losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 100 mg
Study: 8223837
Drug: Nizatidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine (300 mg)
Study: 8223837
Drug: Ranitidine (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (450 mg)
Study: 19508966
Drug: CRx-102 (prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRx-102 (prednisolone 3 mg/day and dipyridamole 400 mg/day)
Study: 16118673
Drug: IFN-alpha monotherapy
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha monotherapy (13 patients) at 9 million units 3 times weekly for 24 weeks
Study: 16118673
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (14 patients) with IFN-alpha at 9 million units 3 times weekly for 24 weeks plus lamivudine 100 mg/day for 1 year
Study: 7742706
Drug: O2‐O3 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: O2‐O3 therapy
Study: 7742706
Drug: HBO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBO therapy
Study: 6825584
Drug: Prednisone (massive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (massive single dose and then alternating daily)
Study: 6825584
Drug: Lymphokinetic drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphokinetic drug (Venalot‐Depot)
Study: 6112444
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of treatments
Study: 30100106
Drug: 0.04 g
Normalized name: Glycerin 0.04 g in 1 g VAGINAL GEL [Inclear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04 g hydrolyzed casein protein×kg ffm-1×2 h-1
Study: 30100106
Drug: 0.10 g
Normalized name: RABBIT 0.10 g in 1 mL SUBCUTANEOUS INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.10 g hydrolyzed casein protein×kg ffm-1×2 h-1
Study: 30100106
Drug: 0.30 g
Normalized name: Titanium Dioxide 0.30 g in 3.5 g TOPICAL POWDER [3CE TRIPLE SHADOW LEMME SEE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30 g hydrolyzed casein protein×kg ffm-1×2 h-1
Study: 24417600
Drug: Individual Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Therapy (IT)
Study: 29510651
Drug: No Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Therapy (NT)
Study: 22379625
Drug: Specialist first-episode
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specialist first-episode treatment plus specialist early intervention for borderline personality
Study: 22379625
Drug: Specialist first-episode
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specialist first-episode treatment alone
Study: 18727459
Drug: High monounsaturated
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High monounsaturated fatty acid diabetes-specific supplement (49.95% calories from fats)
Study: 18727459
Drug: Diabetes-specific supplement
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes-specific supplement (34% calories from fats)
Study: 7163723
Drug: Flurazepam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurazepam (30 mg, nightly for 2 weeks)
Study: 30696255
Drug: Nimesulide 100
Normalized name: nimesulide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 100 mg tablet
Study: 23398716
Drug: 3D conformal
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D conformal treatment planning
Study: 20952427
Drug: Clonidine 2
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 2 µg kg⁻¹ in bupivacaine 0.2%
Study: 20952427
Drug: Morphine 30
Normalized name: ethylmorphine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 30 µg kg⁻¹ in bupivacaine 0.2%
Study: 19192106
Drug: Self-reported use
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported use of ED medications
Study: 17374742
Drug: Intensified maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified maintenance chemotherapy (n = 89)
Study: 15125746
Drug: Gemcitabine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine with radiotherapy (300 mg/m2/week)
Study: 12397466
Drug: Quadramet (samarium‐153
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadramet (samarium‐153 EDTMP) at an average dose of 740 MBq in tracer studies and up to 50 GBq in therapy infusions.
Study: 12397466
Drug: Quadramet (samarium‐153
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadramet (samarium‐153 EDTMP) at an average dose of 740 MBq in tracer studies.
Study: 7661492
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (2.5 g of colestipol plus 2.5 g of psyllium)
Study: 7661492
Drug: Colestipol alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol alone (5 g)
Study: 7661492
Drug: Psyllium alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium alone (5 g)
Study: 7661492
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 g cellulose)
Study: 2034085
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy using large field radiotherapy (total irradiation of 20 Gy, daily fractionation of 4 Gy) and induced hyperglycemia (22‐23 mmol/l)
Study: 2034085
Drug: Induced hyperglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induced hyperglycemia after discontinuation of radiotherapy sessions
Study: 31658148
Drug: Prolonged dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged dual antiplatelet therapy (DAPT) (>12 months)
Study: 30955096
Drug: Piezocision-assisted orthodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piezocision-assisted orthodontic treatment
Study: 30991984
Drug: Conventional orthodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional orthodontic treatment
Study: 28644196
Drug: Cebranopadol 200
Normalized name: Cebranopadol
DrugBank: Cebranopadol (DB12830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cebranopadol 200 μg once daily
Study: 28644196
Drug: Cebranopadol 400
Normalized name: Cebranopadol
DrugBank: Cebranopadol (DB12830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cebranopadol 400 μg once daily
Study: 28644196
Drug: Cebranopadol 600
Normalized name: Cebranopadol
DrugBank: Cebranopadol (DB12830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cebranopadol 600 μg once daily
Study: 28644196
Drug: Tapentadol 200
Normalized name: tapentadol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol 200 mg twice daily
Study: 28644196
Drug: Cebranopadol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cebranopadol (all doses)
Study: 28644196
Drug: Cebranopadol (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cebranopadol (target doses)
Study: 25775881
Drug: Low-concentration iodinated
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-concentration iodinated contrast medium (Iodixanol, 270 mg I/ml) with low tube voltage (80 kV)
Study: 25775881
Drug: High-concentration iodinated
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-concentration iodinated contrast medium (Iodixanol, 320 mg I/ml) with standard tube voltage (120 kV)
Study: 25775881
Drug: Low-concentration iodinated
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-concentration iodinated contrast medium (Iodixanol, 270 mg I/ml)
Study: 25775881
Drug: High-concentration iodinated
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-concentration iodinated contrast medium (Iodixanol, 320 mg I/ml)
Study: 23069363
Drug: Time-based Green
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-based Green Prescription
Study: 17323788
Drug: Ibuprofen sodium
Normalized name: Ibuprofen sodium
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen sodium dihydrate (256 mg sodium salt, equivalent to 200 mg ibuprofen)
Study: 17323788
Drug: Ibuprofen acid
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen acid (200 mg ibuprofen)
Study: 15143880
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy with biweekly administration of 1000 mg/m2 gemcitabine
Study: 9537489
Drug: IgG CPS
Normalized name: methylcellulose (1500 CPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG CPS antibodies against serotypes Ia, II and III
Study: 9537489
Drug: IgM antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgM antibodies against serotype III CPS
Study: 8023538
Drug: Taprostene (T)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taprostene (T) at a continuous infusion of 25 ng/kg/min (in one case 12.5 ng/kg/min)
Study: 2486180
Drug: Gentamicin serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin serum levels determined only if renal dysfunction evident or if patient failed to respond to therapy
Study: 2486180
Drug: Gentamicin serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin serum levels determined after the third dose
Study: 9428939
Drug: Community intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community intervention program including mass health education, nutrition education, antismoking propaganda, detection and treatment of hypertension, diabetes, and hyperlipidemia.
Study: 8491161
Drug: Oily fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oily fish diet (170 g daily for 6 weeks)
Study: 8491161
Drug: White fish
Normalized name: WHITE FISH
DrugBank: White fish (DB10627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White fish diet (170 g daily for 6 weeks)
Study: 3326423
Drug: Droperidol (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (7.5 mg single dose)
Study: 18262140
Drug: Transdermal Scopolamine
Normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal Scopolamine
Study: 29223745
Drug: Buparlisib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib (100 mg per day) plus fulvestrant (500 mg on days 1 and 15 of cycle 1 and on day 1 of subsequent 28-day cycles)
Study: 29223745
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus fulvestrant (500 mg on days 1 and 15 of cycle 1 and on day 1 of subsequent 28-day cycles)
Study: 24860968
Drug: New and
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 27 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 50 mg in 1 mL TOPICAL LOTION [Loreal Paris Age Perfect Rosy Tone SPF 30 Renew and revive healthy tone Visibly younger-looking skin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New and existing pharmacological strategies for constipation treatment
Study: 19038712
Drug: 24-hour pain
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24-hour pain pump with 0.375% ropivacaine infusion at a continuous rate of 5 mL/h
Study: 19038712
Drug: 24-hour pain
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24-hour pain pump with 0.375% ropivacaine infusion
Study: 8843991
Drug: Oral riboflavin
Normalized name: riboflavin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral riboflavin (20, 40, 60 mg)
Study: 8843991
Drug: Oral riboflavin
Normalized name: riboflavin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral riboflavin (40 mg) in female patients with liver cirrhosis
Study: 8843991
Drug: Oral riboflavin
Normalized name: riboflavin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral riboflavin (various doses)
Study: 27296860
Drug: Progressive resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance exercise for 15 weeks, twice per week.
Study: 11783223
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy combined with Chinese herbal medicine (CHM)
Study: 11783223
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy alone (Control)
Study: 30590810
Drug: Group-delivered Acceptance
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-delivered Acceptance and Commitment Therapy (ACT)
Study: 30590810
Drug: Group-delivered Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-delivered Cognitive Behavioral Therapy (CBT)
Study: 25142778
Drug: Laropiprant 100mg
DrugBank: Laropiprant (DB11629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laropiprant 100mg once daily for 4 weeks
Study: 16380237
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (quetiapine, olanzapine, risperidone, clozapine)
Study: 16380237
Drug: Typical antipsychotics
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical antipsychotics (haloperidol, chlorpromazine)
Study: 11443537
Drug: Interferon-alpha (IFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha (IFN alpha) immunotherapy
Study: 9769277
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 micrograms inhaled 15 min prior to L-ASA challenge)
Study: 9769277
Drug: Placebo (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inhaled 15 min prior to L-ASA challenge)
Study: 2826714
Drug: Cyclophosphamide, doxorubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide, doxorubicin, and cisplatin (CAP) followed by mitomycin, lomustine, and methotrexate (MCM) on progression (sequential)
Study: 31416695
Drug: Pump On
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pump On (50% basal insulin at exercise onset)
Study: 31416695
Drug: Pump Off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pump Off (0% basal insulin at exercise onset)
Study: 25554993
Drug: Internet-based preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based preventive program adjunctive to usual pharmacological management
Study: 25554993
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control treatment (directing subjects to healthy living websites)
Study: 21978765
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus carboplatin (GC) - gemcitabine 1,000 mg/m² on days 1 and 8, plus carboplatin AUC 5 on day 1, every 21 days for up to six cycles.
Study: 21978765
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus carboplatin (TC) - paclitaxel 175 mg/m² plus carboplatin AUC 6 on day 1, every 21 days for up to six cycles.
Study: 21978765
Drug: Paclitaxel consolidation
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel consolidation therapy - 135 mg/m² every 28 days for ≤ 12 months, for patients with complete response (CR).
Study: 21978765
Drug: Single-agent crossover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent crossover therapy for patients without CR, at induction doses/schedules until CR, disease progression (PD), or unacceptable toxicity.
Study: 18547152
Drug: 1 cartridge
Normalized name: Product containing precisely somatropin 1 milligram/1 cartridge powder for conventional release solution for injection (clinical drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cartridge phentolamine administered intravenously (1Piv)
Study: 9124194
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and filgrastim (5 microg/kg/day s.c.)
Study: 9124194
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and filgrastim (level 3: day 4 to day 7 and day 10 to day 13)
Study: 9124194
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and filgrastim
Study: 8438597
Drug: Daily supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplements of 26 ml water/kg body weight and 0.16 g sodium chloride/kg body weight during hypokinesia
Study: 3462335
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin administration in 8 SAD patients
Study: 3462335
Drug: Atenolol (beta-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (beta-adrenergic blocker) in 19 SAD patients
Study: 15913898
Drug: Cognitive-behavioral coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral coping skills therapy combined with pharmacotherapy
Study: 10340838
Drug: 75 mg/day
Normalized name: Lyllana 0.075 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/day aspirin (n = 9399)
Study: 21674768
Drug: Cefoperazone-sulbactam (CS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone-sulbactam (CS) 100 mg/kg/day
Study: 21674768
Drug: Piperacillin-tazobactam (PIP/TAZO)
Normalized name: piperacillin / tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam (PIP/TAZO) 360 mg/kg/day
Study: 19358075
Drug: Local anaesthetics
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anaesthetics injection
Study: 3161813
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of conjugated estrogens (CE) daily
Study: 3161813
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of intramuscular depomedroxyprogesterone acetate (DMPA) every 3 months
Study: 28383836
Drug: Indacaterol/glycopyrronium 110/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol/glycopyrronium 110/50 μg (IND/GLY) once daily
Study: 28383836
Drug: Salmeterol/proprionate of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/proprionate of fluticasone 50/500 μg (SAL/FC) twice daily
Study: 25047458
Drug: edoxaban 15
Normalized name: edoxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: edoxaban 15 mg once daily
Study: 25047458
Drug: edoxaban 30
Normalized name: edoxaban 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: edoxaban 30 mg once daily
Study: 25047458
Drug: enoxaparin 2000
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: enoxaparin 2000 IU (20 mg) twice daily
Study: 22171728
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT), 6 sessions
Study: 15889952
Drug: Oral quetiapine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral quetiapine
Study: 18454611
Drug: Single music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single music therapy intervention
Study: 12527977
Drug: 15-Pre (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-Pre (75 g glucose dissolved in 500 ml water, ingested 15 min before exercise)
Study: 12527977
Drug: 45-Pre (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45-Pre (75 g glucose dissolved in 500 ml water, ingested 45 min before exercise)
Study: 12527977
Drug: 75-Pre (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75-Pre (75 g glucose dissolved in 500 ml water, ingested 75 min before exercise)
Study: 10231449
Drug: L-arginine (17
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (17 mg/kg/min over 30 min)
Study: 27466218
Drug: Exenatide (EXE)
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide (EXE) twice daily (BID)
Study: 31907737
Drug: Treatment duration
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment duration
Study: 23216646
Drug: NicVAX® co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: NicVAX® co-administered with varenicline (Champix®)
Study: 23216646
Drug: placebo co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo co-administered with varenicline (Champix®)
Study: 20405011
Drug: Directly observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly observed highly-active antiretroviral therapy (DOT)